<DOC>
	<DOCNO>NCT00115505</DOCNO>
	<brief_summary>This research trial study quality life , employment , informal care cost analysis patient breast cancer receive chemotherapy . This trial assess quality life affect cancer , cancer treatment cause change patient 's spouse 's employment affect patient extend family , impact peripheral neuropathy cause chemotherapy quality life . Learning quality life informal care cost may help doctor good understand patient feel treatment , effect medicine , future may help patient doctor decide medicine use treat cancer .</brief_summary>
	<brief_title>Quality Life , Employment , Informal Care Costs Women Who Are Receiving Chemotherapy Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare individual treatment arm relative degree symptom interfere patient function characterize compare relative duration symptom interfere patient functioning . II . To assess employment consequence cancer treatment patient extend family , compare treatment arm relative consequence . III . To determine prevalence severity peripheral neuropathy breast cancer patient treat adjuvant chemotherapy dose dense ( every two week ) paclitaxel 4 cycle , study entry 5 year start treatment . SECONDARY OBJECTIVES : I . To identify baseline characteristic predictive patient vulnerable experience side effect significantly interfere patient functioning . II . To identify characterize relative importance reason patient decide participate treatment study ( Cancer Leukemia Group B [ CALGB ] 40101 ) reason might change consequence experience treatment . III . To compare quality-adjusted life year adjuvant chemotherapy ( AC ) paclitaxel short long schedule , regardless factor . IV . To measure , course adjuvant therapy , type amount informal care need patient . V. Using societal perspective , estimate compare economic consequence employment informal care need . VI . To determine specific identifiable clinical adverse event ( i.e. , neuropathy fatigue ) associate great economic consequence . VII . To examine factor predictive patient employ cancer treatment . VIII . To compare prevalence severity peripheral neuropathy breast cancer patient treat dose dense paclitaxel patient treat dose dense CA ( cyclophosphamide doxorubicin ) . IX . To conduct exploratory examination relationship severity peripheral neuropathy paclitaxel treatment ( 4 6 cycle ) breast cancer patient ' functioning , include physical , psychological , social functioning . X . To validate neurotoxicity item Symptoms Relation Patient Functioning Survey ( C-1271 ) use protocol correlate result Functional Assessment Cancer Therapy ( FACT ) -Neurotoxicity Subscale ( C-669 ) European Organization Research Treatment Cancer ( EORTC ) Quality Life Questionnaire ( QLQ ) -Core ( C ) 30 Breast Cancer module ( C-259 C-618 ) . OUTLINE : Patients complete QOL Assessments comprise Subjective Significance Questionnaire , Medical Outcome Study ( MOS ) Social Support Survey , Patient Preferences , CALGB Background Information , European Quality Life 5-Dimensions ( EQ-5D ) QOL Assessment Form ; Employment Informal Care Cost Assessments ; Peripheral Neuropathy FACT-NTX subscale baseline , 29-42 57-70 day , 9 18 month . Patients meet cut-off score peripheral neuropathy FACT-NTX subscale 18 month complete Symptoms Relation Patient Functioning Survey , FACT-NTX subscale , EORTC QLQ-C30 , EORTC QLQ-BR23 , Medications Used Treating Peripheral Neuropathy 24 , 36 , 48 , 60 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Patient must register CALGB 40101 Patient must able communicate English</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>estrogen receptor-negative breast cancer</keyword>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>progesterone receptor-negative breast cancer</keyword>
	<keyword>progesterone receptor-positive breast cancer</keyword>
</DOC>